Top 10 Warren Buffett Stocks For 2014

Procter & Gamble (PG) is generally regarded as one of the best consumer staple stocks that's currently available for purchase. P&G is a U.S.-based company that produces a large portfolio of consumer goods like cleaners, health products, and pet foods. Behind A.G. Lafley, its CEO, P&G raked in over $80 billion in revenues in 2012. It's commonly regarded as an incredibly safe investment vehicle and has been a favorite of many fund success stories, including that of Warren Buffett.

If P&G isn't a widely known name, the products that it makes almost certainly are. P&G is responsible for such brands as Bounty, Charmin, Crest, Dawn, Downy, Duracell, Febreze, Gillette, Iams, Pampers, Pantene, Tide and Vicks - how many of these do you have floating around your house right now? Did you know that many of the items you consistently use and buy on a daily basis are P&G products?

The Buffett school of common sense states that these are exactly the types of companies that make attractive investments. I commented on this in My 17 Definitive Cardnial Rules for Investing Success, where I stressed applying common sense to your positions.

Top 10 Construction Companies To Buy For 2015: Peoples Bancorp Inc.(PEBO)

Peoples Bancorp Inc. operates as a holding company for Peoples Bank, National Association that provides financial products and services. It offers commercial and retail banking, insurance, brokerage, and trust services. The company accepts various deposit products, including demand deposit accounts, savings accounts, money market accounts, and certificates of deposit; and provides commercial, consumer, and real estate mortgage loans, as well as lines of credit. It also offers debit and automated teller machine (ATM) cards; corporate and personal trust services; safe deposit rental facilities; travelers checks, money orders, and cashier?s checks; and telephone and Internet-based banking services. In addition, the company provides a range of life, health, and property and casualty insurance products; and fiduciary and wealth management services. Further, it offers brokerage services through an unaffiliated registered broker-dealer; and credit cards to consumers and business es, as well as provides merchant credit card processing services through joint marketing arrangements with third parties. The company offers its financial products and services through 47 financial service locations and 40 ATMs in southeastern Ohio, northwestern West Virginia, and northeastern Kentucky. Peoples Bancorp Inc. was founded in 1902 and is based in Marietta, Ohio.

Advisors' Opinion:

• [By Marc Bastow]

  Marietta, Ohio-based bank holding company Peoples Bancorp (PEBO) raised its quarterly dividend 7% to 15 cents per share, payable on Feb. 18 to shareholders of record as of Feb. 3.
  PEBO Dividend Yield: 2.60%

Top 10 Warren Buffett Stocks For 2014: Palo Alto Networks Inc (PANW)

Palo Alto Networks, Inc., incorporated in March 2005, offers a network security platform that allows enterprises, service providers, and government entities to secure their networks. The core of its platform is the Company�� firewall that delivers natively integrated application, user, and content visibility and control through its operating system, hardware, and software architecture. The Company primarily sells its products and services to end-customers through distributors, resellers, and partners, and directly to end-customers (collectively partners), who are supported by its sales and marketing organization, in the Americas, in Europe, the Middle East, and Africa (EMEA), and in Asia Pacific and Japan (APAC). Its products and services can address a range of its end-customers��network security requirements, from the data center to the network perimeter, as well as the distributed enterprise, which includes branch offices and a number of mobile devices. It introduced PA-5000 Series and GlobalProtect subscription service in March 2011 and the PA-200 and WildFire subscription service in November 2011.

The Company�� platform is delivered in an appliance form factor and includes a suite of subscription services, as well as support and maintenance. Its subscription services can be activated on any of its appliances. All of the Company�� appliances incorporate its PAN-OS operating system and are based on its identification technologies, App-ID, User-ID, and Content-ID, which allow security policies to be defined within the context of applications, users, and content. It delivers these capabilities through a single-pass parallel processing architecture that simultaneously performs multiple identification, security and networking functions. The Company serves the enterprise network security market, which consists of Firewall/ Virtual Private Network (VPN), Unified Threat Management (UTM), Web Gateway, Intrusion Detection and Prevention (IDP/IPS), and VPN technologies. The Company deriv! ed 62% of its total revenue from the Americas, 27% from Europe, the Middle East, and Africa (EMEA), and 11% from Asia Pacific and Japan (APAC) as of January 31, 2012.

The Company derives revenue from sales of its products and services, which together comprise its platform. Product revenue is primarily generated from sales of its Firewall. The Company�� Threat Prevention, universal resource locator (URL) Filtering, and GlobalProtect subscriptions provide its end-customers with real-time access to the antivirus, intrusion prevention, Web filtering, and malware protection capabilities across fixed and mobile devices. The Company�� application classification engine, called App-ID, uses multiple identification techniques to determine the exact identity of applications traversing the network. App-ID is the foundational classification engine that provides the core traffic classification to all other functions in its platform. The App-ID classification is used to invoke other security functions.

App-ID uses a series of classification techniques to identify an application. App-ID classifies all network traffic, including business applications, consumer applications, and network protocols, across all ports. User-ID integrates its platform with a range of enterprise user directories and technologies, including Active Directory, eDirectory, Open LDAP, Citrix Terminal Server, Microsoft Exchange, Microsoft Terminal Server, and ZENworks. Content-ID is a collection of technologies that enables its subscription services. Content-ID combines a real-time threat prevention engine, cloud-based analysis service, and a URL categorization database to limit unauthorized data and file transfers, detect and block a range of threats, and control non-work related Web surfing. Its WildFire, cloud-based analysis service provides a real-time analysis engine for detecting previously unseen malware. Its URL filtering database consists of millions of URLs across many categories and is designed to monitor a! nd contro! l employee Web surfing activities. Single-Pass Parallel Processing Architecture (SP3) has two elements: single-pass software and parallel processing hardware.

The PAN-OS Operating System operating system provides the foundation for its network security platform and contains App-ID, User-ID, and Content-ID. PAN-OS performs the core functions of its platform, while also providing the networking, security, and management functions needed for implementation. The PAN-OS networking functions include dynamic routing, switching, high availability, and VPN support, which enables deployment into a range of networking environments. PAN-OS also includes attack protection capabilities, such as blocking invalid or malformed packets, IP defragmentation, TCP reassembly, and network traffic normalization. The Company also offers, such as application traffic management, solution design and planning, configuration, and firewall migration. Its education services provide classroom-style training and are primarily delivered through its partners.

The Company competes with Cisco, Juniper, Intel, IBM, HP, Check Point Software, Fortinet and Sourcefire.

Advisors' Opinion:

• [By Brian Nichols]

  The growth of security
  If Cisco were to make a splash by acquiring Juniper, it would obtain a declining security business, which might have good synergies with Cisco's own security segment. However, Cisco is not losing market share to Juniper in this segment. Instead, tech giant Oracle and smaller rival�Palo Alto Networks (NYSE: PANW  ) are hindering Cisco's performance.

• [By Sue Chang]

  Palo Alto Networks Inc. (PANW) �is forecast to report earnings of 10 cents a share in the fiscal third quarter.

• [By Dan Caplinger]

  On the other side of the spectrum is Palo Alto Networks (NYSE: PANW  ) , which has fallen 10% following its earnings report last night. Citing federal spending cuts and poor conditions in Europe, Palo Alto reported weaker-than-expected sales despite seeing year-over-year growth of 54%. Even worse, the company expects current-quarter revenue growth to slow to about 42% year over year, reflecting a much faster deceleration than the stock's valuation implied. Given the huge amount of competition in the data- and cyber-security industry, Palo Alto and its virtual firewalls aren't guaranteed to win out over the company's rivals.

• [By Lauren Pollock]

  Palo Alto Networks Inc.'s(PANW) fiscal first-quarter loss widened as the Internet security company spent more on sales and marketing and other expenses, more than offsetting a jump in revenue. But shares climbed 9.9% to $50.65 premarket as results for the latest period exceeded Wall Street’s expectations.

Top 10 Warren Buffett Stocks For 2014: Sagent Pharmaceuticals Inc.(SGNT)

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. It offers a range of products across anti-infective, oncolytic, and critical care indications in various presentations, including single-and multi-dose vials, pre-filled ready-to-use syringes, and premix bags. The company?s anti-infective products include Levofloxacin, a fluoroquinolone antibacterial for the treatment of various infections caused by susceptible bacteria in adults of age 18 years or older; and Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structure, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients. Its oncology products comprise Gemcitabine, a nucleoside metabolic inhibitor used for the treatment of ovarian, breast, lung, and panc reatic cancers; and Topotecan, a topoisomerase inhibitor for small cell lung cancer sensitive disease. The company also offers critical care products consisting of Adenosine, an antiarrhythmic used for the treatment of cardiac rhythm disturbances; and Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2011, it marketed 33 generic injectable products; and had a new product pipeline that included 36 products represented by 63 Abbreviated New Drug Applications (ANDAs). The company sells its products to pharmaceutical wholesale companies, which then distribute the products to end-user hospitals, long-term care facilities, alternate care sites, and clinics. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

Advisors' Opinion:

• [By John Seward]

  Among the changes announced Tuesday, Affiliated Managers Group (NYSE AMG) will replace Forest Laboratories Inc. (NYSE: FRX) in the S&P 500 after the close of trading on Monday, June 30. LaSalle Hotel Properties (NYSE: LHO) will replace Affiliated Managers in the S&P MidCap 400 and Sagent Pharmaceuticals Inc. (NASDAQ: SGNT) will replace LaSalle in the S&P SmallCap 600.

• [By CRWE]

  Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, reported financial results for the quarter ended March 31, 2012.

• [By Rich Smith]

  Sagent Pharmaceuticals (NASDAQ: SGNT  ) �is recalling three lots of Vecuronium Bromide for Injection, 10mg (NDC number 25021-657-10). Vecuronium Bromide for Injection is a neuromuscular blocking agent used in addition to general anesthesia to facilitate insertion of endotracheal tubes, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.�

Top 10 Warren Buffett Stocks For 2014: Cytec Industries Inc (CYT)

Cytec Industries Inc/De/, formerly Cytec Industries Inc., incorporated on December 17, 1993, is a specialty chemicals and materials company focused on developing, manufacturing and selling value-added products. Its products serve a diverse range of end markets, including aerospace and industrial materials, mining and plastics. The Company has four business segments: Engineered Materials, Umeco, In-Process Separation and Additive Technologies. Engineered Materials segment principally includes advanced composites, carbon fiber, and structural film adhesives. The Umeco segment includes composite and process materials, primarily for the aerospace and defense, wind energy, automotive, recreation and other industrial segments. The In Process Separation segment includes mining chemicals and phosphines. The Additive Technologies segment includes polymer additives, specialty additives and formulated resins. On July 20, 2012, the Company acquired Umeco plc.

Engineered Materials

The Engineered Materials segment is a global provider of technologically advanced materials for aerospace, high-performance industrial and other extreme-demand markets. Its primary product lines are advanced aerospace composites and structural adhesives, High performance industrial materials and Carbon fibers. Its major products in the advanced aerospace composites include aerospace- qualified prepregs, resin infusion systems and structural/surfacing adhesives. Its principal applications include commercial airliners, regional and business jets, military aircraft, including rotorcraft, satellites and launch vehicles. The products in the high performance industrial materials include Industrial-grade prepregs, resin infusion systems and structural/surfacing adhesives. Its applications include high performance automotive, defense, tooling and alternative energy. The products in carbon fibers include high performance fiber carbon fibers. Its applications include reinforcements for advanced aerospace and industrial c! omposites.

The Company is a supplier to the F-35 Joint Strike Fighter and F-18 fighter jet programs. It is also a supplier for the business and regional jet market, supporting programs, such as Bombardier�� CSeries and LearJet85. It also manufactures specialty adhesive forms for complex composites assemblies, such as honeycomb and sandwich structures and special surfacing films to provide aircraft lightning strike protection. It manufactures and sells various high-performance grades of both polyacrylonitrile (PAN) type and pitch type carbon fibers used as a reinforcement material for aerospace and other extreme-demand and high-performance composites.

The Company�� High Performance Industrial Materials (HPIM) product line strategy is to leverage its composites, adhesives and resin technologies across multiple industrial markets. The Company supplies composites and adhesives to a spectrum of markets, such as high performance and luxury low-rate serial automotive, defense, and alternative energy.

Umeco

Umeco�� primary product lines are High performance composites structural materials/solutions and Composite process materials/solutions. Its major products in the High performance composites structural materials/solutions include Aerospace-qualified prepregs, Industrial-grade prepreg. Its principal applications include large commercial airliners, military aircraft, high performance automotive, defense, tooling, recreation, industrial and alternative energy. The products in Composite process materials/solutions include Process materials/solutions including vacuum bagging, release films and sealant tapes. Its principal applications include large commercial airliners, military aircraft, high performance automotive, defense, tooling, recreation, industrial and alternative energy and Process materials for the forming, infusion, curing of composite structures.

The Company�� structural materials product line includes the development, manufa! cturing a! nd supply of advanced composite materials. It specializes in the manufacture of composite materials for a range of industries such as aerospace and defense, marine, motor sport and automotive, construction, wind energy, and recreation.

In-Process Separation

The In-Process Separation segment includes mining chemicals and phosphines. The Company�� mining chemicals product line include flotation promoters, collectors, frothers, dispersants and depressants, solvent extractants, flocculants, filter and dewatering aids, antiscalants, and defoamers . Its principal applications include mineral separation and processing for copper, alumina, cobalt, nickel, and other minerals. Its Phosphines include flame retardants, catalyst ligands, high purity phosphine gas and biocides.

Its phospine based specialty products are used primarily in the pharmaceutical, chemical and electronic manufacturing, and fumigation. Its patented MaxHT antiscalant is sold for suppressing sodalite scale formation. Its phosphine specialties are utilized for a variety of applications. It is a supplier of ultra- high purity phosphine gas, used in semiconductor manufacturing and light emitting diode applications, various phosphine derivative products, including phosphonium salts used in pharmaceutical catalysts and biocides. Included in the phosphine line are organo phosphorus compounds. The compounds are used primarily as intermediates and catalyst ligands for organic and chemical synthesis in the pharmaceutical and chemical industries.

Additive Technologies

The Additive Technologies segment includes polymer additives specialty additives and Formulated resins. Polymer additives include ultraviolet light stabilizers and absorbers, high performance antioxidants and antistatic agents. Its applications include plastics, coatings, and fibers for: agricultural films, automotive parts, architectural lighting, housewares, packaging, outdoor furniture, sporting goods, toys and apparel.! Specialt! y additives include surfactants, specialty monomers, resin amines, and PTZ Phenothiazine. Its Formulated resins are used in for bonding or sealing of electrical and electronic components.

The Company markets its Additive Technologies chemicals through specialized sales and technical service staffs for each of its product lines. Sales are usually made directly to customers and through distributors to smaller customers. The Company is a global supplier to the plastics industry of specialty additives, which protect plastics from the ultraviolet radiation of sunlight and from oxidation. It is a global supplier of sulfosuccinate surfactants, Docusate sodium, and PTZ phenothiazine. Sulfosuccinate surfactants and acrylamide-based specialty monomers products are used in emulsion polymers, paints, paper coatings, printing inks, and other diverse customer applications. Docusate is a pharmaceutical grade product used as both an active ingredient and excipient/formulating aid. PTZ phenothiazine is primarily used as an acrylic acid, acrylic ester and methacrylate monomer stabilizer.

Advisors' Opinion:

• [By alicet236]

  Vice President and CFO of Cytec Industries Inc. (CYT) David Drillock sold 49,038 shares on July 21 at an average price of $107.06. The total transaction amount was $5,250,008.

Top 10 Warren Buffett Stocks For 2014: Brookline Bancorp Inc.(BRKL)

Brookline Bancorp, Inc. operates as the holding company for Brookline Bank, Bank Rhode Island, and The First National Bank of Ipswich, which provide commercial and retail banking services, and cash management and investment services to customers in Central New England. The company accepts various deposit products, including non-interest-bearing checking accounts, interest-bearing NOW accounts, savings accounts and money market savings accounts, certificate of deposit accounts, individual retirement accounts, and other qualified plan accounts. Its loan portfolio comprises first mortgage loans secured by commercial, multi-family, and residential real estate properties; auto loans; loans to business entities consisting of commercial lines of credit; and loans to condominium associations, as well as loans for financing equipment used by small businesses. Brookline Bancorp, Inc. also provides financing for construction and development projects, home equity, and other consumer l oans; and loans to finance coin-operated laundry, dry cleaning, and convenience store equipment and businesses. As of January 25, 2012, it operated 43 branches in Massachusetts and Rhode Island. The company was founded in 1871 and is headquartered in Brookline, Massachusetts.

Advisors' Opinion:

• [By CRWE]

  Brookline Bancorp, Inc. (NASDAQ:BRKL) announced today that it will report third quarter earnings 2012 at the close of business Wednesday, October 24, 2012. Management will host a conference call to review this information at 1:30 PM Eastern Time on Thursday, October 25, 2012.

Top 10 Warren Buffett Stocks For 2014: Cleco Corporation (CNL)

Cleco Corporation, through its subsidiaries, engages in the generation, transmission, distribution, and sale of electricity in Louisiana. As of December 31, 2009, it had ownership interest in 3 steam electric generating stations and 1 gas turbine with a combined name plate capacity of 1,359 megawatts, and a combined electric net generating capacity of 1,318 megawatts. The company served approximately 277,000 customers in 107 communities in the central and southeastern Louisiana. It also owns and operates a natural gas-fired merchant power plant, as well as has a 50% interest in another natural gas-fired merchant power plant located in Louisiana. Cleco Corporation was founded in 1934 and is based in Pineville, Louisiana.

Advisors' Opinion:

• [By David Dittman]

  Answer: I like NextEra Energy, which has significant renewables exposure and operates in a region with solid economic fundamentals. I also like smaller utes that operate in smaller footprints with solid long-term fundamentals, including Cleco (NYSE: CNL), Pinnacle West, Vectren (NYSE: VVC) and SCANA (NYSE: SCG).

Top 10 Warren Buffett Stocks For 2014: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors' Opinion:

• [By Leo Sun]

  Prosensa: GSK doesn't believe in it -- so why should you?
  Throughout 2013, Prosensa and its former partner GlaxoSmithKline competed against Sarepta Therapeutics (NASDAQ: SRPT  ) to launch the first dedicated treatment for Duchenne muscular dystrophy (DMD).

• [By Keith Speights]

  Something bold
  Buying shares in Sarepta Therapeutics (NASDAQ: SRPT  ) requires more boldness from investors than buying J&J stock, but I still think it's a smart idea over the long run. Sarepta is up 33% for the year, but shares have sank nearly 13% in the past few weeks.